Hero

Celyad Announces February and March 2020 Conference Schedule

1

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders

2

Letter to Shareholders

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

3

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

4

Development of the Next Generation NKG2D CAR T-cell Manufacturing Process

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad Announces February and March 2020 Conference Schedule

Celyad Announces February and March 2020 Conference Schedule

Letter to Shareholders - January 2020

Letter to Shareholders - January 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Discover all news

Carousel

Social Feed

RT @blake_aftab: Peggy Sotiropoulou @CelyadSA Director of Research and Development presenting NKG2D #TCellRx #Immunotherapy platform at #CA…

3 hours ago

RT @blake_aftab: Peggy Sotiropoulou @CelyadSA Director of Research and Development presenting NKG2D #TCellRx #Immunotherapy platform at #CA…

RT @UCLTRO: Interesting talk from Peggy Sotiropoulou @CelyadSA, who presents their pipeline progression of autologous and allogeneic CAR-T…

3 hours ago

RT @UCLTRO: Interesting talk from Peggy Sotiropoulou @CelyadSA, who presents their pipeline progression of autologous and allogeneic CAR-T…

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer ! $CYAD https://t.co/lxKdhLCzYh

9 hours ago

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer ! $CYAD https://t.co/lxKdhLCzYh

JOIN NOW: Hear our Chief Executive Officer, Filippo Petti present LIVE at the SVB Leerink 9th Annual Global Healthc… https://t.co/A03uMGZ5rf

21 hours ago

JOIN NOW: Hear our Chief Executive Officer, Filippo Petti present LIVE at the SVB Leerink 9th Annual Global Healthc… https://t.co/A03uMGZ5rf

RT @blake_aftab: Peggy Sotiropoulou @CelyadSA Director of Research and Development presenting NKG2D #TCellRx #Immunotherapy platform at #CA…

3 hours ago

RT @blake_aftab: Peggy Sotiropoulou @CelyadSA Director of Research and Development presenting NKG2D #TCellRx #Immunotherapy platform at #CA…

RT @UCLTRO: Interesting talk from Peggy Sotiropoulou @CelyadSA, who presents their pipeline progression of autologous and allogeneic CAR-T…

3 hours ago

RT @UCLTRO: Interesting talk from Peggy Sotiropoulou @CelyadSA, who presents their pipeline progression of autologous and allogeneic CAR-T…

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer ! $CYAD https://t.co/lxKdhLCzYh

9 hours ago

Celyad is listed in the top 20 EU immuno-oncology companies that are fighting cancer ! $CYAD https://t.co/lxKdhLCzYh

JOIN NOW: Hear our Chief Executive Officer, Filippo Petti present LIVE at the SVB Leerink 9th Annual Global Healthc… https://t.co/A03uMGZ5rf

21 hours ago

JOIN NOW: Hear our Chief Executive Officer, Filippo Petti present LIVE at the SVB Leerink 9th Annual Global Healthc… https://t.co/A03uMGZ5rf